Levetiracetam study to lower dementia risk in Parkinson’s
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether an added medication strategy can change brain targets linked to memory decline in people with Parkinson’s disease, including those with no memory problems or mild memory changes. It may help lower risk of developing dementia, but you must be able to safely do MRI scans and meet other health and medication rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be diagnosed with Parkinson’s disease with amnestic mild cognitive impairment OR have Parkinson’s but no memory impairment, OR be a healthy volunteer
- Be able to safely have MRI brain scans (no medical reason you cannot get an MRI)
- Do not currently have dementia or vascular dementia
- No history of bipolar disorder or schizophrenia, and no active alcohol or substance abuse
- No major depression, suicidal thoughts, or serious difficulty following study steps
- Not be sensitive to levetiracetam, and you must not use certain anti-seizure or other excluded medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a monoclonal antibody (a type of medicine that targets amyloid, a protein that builds up in the brain) can help people who have both Parkinson's disease and early signs of memory problems or dementia. The study uses brain imaging to confirm amyloid buildup before enrolling patients.
This trial tests a supplement called tributyrin to see if it can help with thinking and memory problems in people with Parkinson's disease. You may be able to join if you have both Parkinson's and mild cognitive impairment or dementia.
This early-stage study looks at electrical seizure-like activity in the brain in people with mild cognitive impairment or Alzheimer’s disease. It aims to understand whether this brain activity is linked to Alzheimer’s and to assess safety and responses.
This study uses a special brain wave test (high-density EEG) to learn more about mild memory problems and how they might be linked to Parkinson's disease. If you join, you'll help researchers understand brain activity patterns that could lead to better diagnosis and care.
This Phase 2 study tests whether the cholesterol medicine atorvastatin can improve how well blood vessels in the brain respond in people with mild cognitive impairment (MCI). It may help brain circulation and possibly slow thinking and memory problems.
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.